Fragment-based Drug Discovery Industry – New Era Of Drug Discovery

Fragment-based drug discovery has been recognized as a potential method to design novel molecules as this technique discovery utilizes comparatively small libraries of ‘fragments or ligands’ that are of low-molecular weights. Factors such as less time-consumption and easy access to biophysical fragment screening techniques are driving the growth of the global fragment-based drug discovery market. However, certain factors such as lower level of potency in few compounds derived from fragment screening and requirement of unique ‘fragment libraries’ for performing the studies might pull back the growth of fragment-based drug discovery market.

Based on service component, the global fragment-based drug discovery market has been segmented into fragment screening and fragment optimization. Fragment screening segment dominated the market in 2014 due to high number of probable hit compounds identified through these techniques. Fragment screening segment is further categorized into biophysical and non-biophysical technique. Under the biophysical technique segment, nuclear magnetic resonance (NMR) spectroscopy held the majority market share in 2014. High sensitivity and moderate protein consumption of the method are the factors contributing to the high market share of the segment. However, the fluorescence polarization segment is expected to grow at the highest CAGR during the forecast period as this method requires the least maintenance, and shows rapid qualitative analysis of diverse molecular interactions.

The end-user segment in the fragment-based drug discovery market has been categorized into biopharmaceutical companies, CROs, and academic and research institutions. Biopharmaceutical companies was witnessed as the largest segment in terms of revenue in 2014. The segment is also expected to expand at the highest CAGR. The dominance of biopharmaceutical companies was attributed to increasing demand for fragment-based drug discovery in a number pharmaceutical companies for the identification of lead compounds in drug discovery process.

Geographically, North America accounted for the largest share of the global fragment-based drug discovery market in 2014. Factors attributed to the dominant position of North America in fragment-based drug discovery market are presence of a large number of pharmaceutical companies in the U.S. and ever-growing awareness of the population regarding fragment-based drug discovery market. However, Asia Pacific is anticipated to witness the highest growth during the forecast period. Key factors such as increasing research and development in various emerging economies, and greater demand for improved and modern healthcare infrastructures would accentuate the growth of fragment-based drug discovery market in Asia Pacific.

Get a Sample of this Report:

The global fragment-based drug discovery market is fragmented due to the presence of numerous established as well as emerging players. The prominent companies operating in the fragment-based drug discovery market are Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica AB, BioFocus, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Emerald BioStructures, Evotec AG, Kinetic Discovery, Proteros Fragments, Sprint Bioscience, Structure Based Design, and Sygnature Discovery.

Contact us:

Mr. Sudip S

Transparency Market Research

90 State Street,

Suite 700,


NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453